| 4.495 -0.125 (-2.71%) | 10-07 12:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.46 | 1-year : | 7.44 |
| Resists | First : | 5.53 | Second : | 6.36 |
| Pivot price | 5.03  |
|||
| Supports | First : | 4.19 | Second : | 3.49 |
| MAs | MA(5) : | 4.47 |
MA(20) : | 5.22 |
| MA(100) : | 5.15 |
MA(250) : | 5.69 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 10.1  |
| RSI | RSI(14): 40 |
|||
| 52-week | High : | 8.89 | Low : | 3.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALEC ] has closed above bottom band by 24.6%. Bollinger Bands are 59.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.63 - 4.66 | 4.66 - 4.69 |
| Low: | 4.22 - 4.25 | 4.25 - 4.29 |
| Close: | 4.56 - 4.62 | 4.62 - 4.68 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Wed, 02 Oct 2024
View On Upcoming Q4 Biotech Catalysts: Part 1 (ALEC, ARVN, AMLX) (NASDAQ:ALEC) - Seeking Alpha
Thu, 26 Sep 2024
We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully - Simply Wall St
Mon, 23 Sep 2024
Alector (NASDAQ:ALEC) Shares Down 5.6% - MarketBeat
Fri, 06 Sep 2024
Alector shares hold as Cowen reiterates Buy on key catalysts - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 97 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 86 (%) |
| Shares Short | 3,460 (K) |
| Shares Short P.Month | 3,680 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.54 |
| Profit Margin | -290.7 % |
| Operating Margin | -302.4 % |
| Return on Assets (ttm) | -18.3 % |
| Return on Equity (ttm) | -92.7 % |
| Qtrly Rev. Growth | -73.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.56 |
| EBITDA (p.s.) | -1.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -217 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -2.48 |
| PEG Ratio | 0.2 |
| Price to Book value | 2.88 |
| Price to Sales | 7.87 |
| Price to Cash Flow | -2.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|